Nisa Investment Advisors
RXRX icon

Nisa Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Nisa Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Buy
14,011
+11,374
+431% +$37.9K ﹤0.01% 1845
2026
Q1 		$8.1K Buy
2,637
+1,265
+92% +$4.89K ﹤0.01% 2310
2025
Q4 		$5.61K Sell
1,372
-59,886
-98% -$297K ﹤0.01% 2429
2025
Q3 		$299K Buy
61,258
+57,443
+1,506% +$302K ﹤0.01% 1160
2025
Q2 		$19.3K Buy
3,815
+870
+30% +$4.27K ﹤0.01% 1957
2025
Q1 		$15.6K Buy
2,945
+459
+18% +$3.35K ﹤0.01% 1980
2024
Q4 		$16.8K Buy
2,486
+158
+7% +$1.06K ﹤0.01% 1990
2024
Q3 		$15.3K Buy
2,328
+303
+15% +$2.17K ﹤0.01% 1988
2024
Q2 		$15.2K Buy
2,025
+748
+59% +$6.52K ﹤0.01% 2036
2024
Q1 		$12.7K Buy
1,277
+122
+11% +$1.36K ﹤0.01% 1996
2023
Q4 		$11.4K Sell
1,155
-2,865
-71% -$20.4K ﹤0.01% 2015
2023
Q3 		$30.8K Sell
4,020
-20
-0.5% -$200 ﹤0.01% 1876
2023
Q2 		$30.2K Sell
4,040
-46,310
-92% -$324K ﹤0.01% 1936
2023
Q1 		$336K Buy
50,350
+20
+0% +$159 ﹤0.01% 1180
2022
Q4 		$388K Sell
50,330
-54
-0.1% -$530 ﹤0.01% 1191
2022
Q3 		$536K Sell
50,384
-26,996
-35% -$273K ﹤0.01% 1007
2022
Q2 		$630K Buy
77,380
+76,300
+7,065% +$511K 0.01% 974
2022
Q1 		$8K Buy
+1,080
New +$11.5K ﹤0.01% 2246
2021
Q4 		– Sell
-2,777
Closed -$64K – 2309
2021
Q3 		$64K Buy
+2,777
New +$78.7K ﹤0.01% 1868

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nisa Investment Advisors's RXRX Position: Q2 2026 in Review

Nisa Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 431% in Q2 2026, buying an estimated $37.9K and bringing the position to 14,011 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Nisa Investment Advisors first reported a position in RXRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $630K in Q2 2022. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Nisa Investment Advisors held 14,011 shares of Recursion Pharmaceuticals worth $51.4K as of Q2 2026.
  • Nisa Investment Advisors bought 11,374 Recursion Pharmaceuticals shares in Q2 2026, an estimated $37.9K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1845 holding.
  • Nisa Investment Advisors first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Nisa Investment Advisors's Recursion Pharmaceuticals position peaked at $630K in Q2 2022.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.